Assessment of fetal brain health via circulating exRNA carriers for opioid use disorder in pregnancy

通过循环 exRNA 载体评估妊娠期阿片类药物使用障碍的胎儿大脑健康

基本信息

  • 批准号:
    10722040
  • 负责人:
  • 金额:
    $ 71.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary We are submitting this proposal in response to PAR-20-147 (Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection). The opioid epidemic in the United States has far reaching consequences for public health. In recent decades, the rate of newborns born with neonatal abstinence syndrome (NAS) has increased dramatically. However, not all neonates exposed to opioids during gestation develop NAS or require treatment. NAS is a complex and idiosyncratic condition, and it is currently not possible to predict even at birth which infants will require pharmacotherapy or be susceptible to its worst outcomes. Accessible biomarkers for fetal brain and CNS development during opioid exposure would be highly valuable for deciding which infants will need opioid therapy for NAS and making personalized risk assessments for opioid exposed infants. They could also shed light on the biological pathways that lead to the worst effects of opioid exposure during gestation. Extracellular vesicles (EVs) derived from the Fetal brain and central Nervous system (FNEV) can cross the fetal/placental barrier and can be isolated from maternal blood. They represent a powerful accessible tool to provide insight on fetal neurodevelopment and damage. However, EVs are highly heterogeneous, with a diverse set of surface proteins and intra-vesicular cargo, such as RNA. Current approaches to the isolation and study of EVs lack the necessary sensitivity and precision to characterize EV subpopulations. To address the current limitations of EV analyses, we developed a high-throughput single-EV flow analyzer and sorter capable of detecting single dye molecules. This new technical capability allows us to exquisitely define the profiles of plasma FNEV during pregnancy. Our studies could lead to assays that define NAS risk pre-birth and bring new insights into the mechanistic pathways of fetal brain injury.
项目摘要 我们提交此提案是为了响应PAR-20-147(细胞外RNA载体亚类, 与物质使用障碍或艾滋病毒感染有关的过程)。 阿片类药物在美国的流行对公共卫生产生了深远的影响。近几十年来, 患有新生儿戒断综合征(NAS)的新生儿的比率急剧增加。但并非 所有在妊娠期间暴露于阿片类药物的新生儿都会发生NAS或需要治疗。NAS是一个复杂的, 特异质条件,目前甚至在出生时也不可能预测哪些婴儿将需要 药物治疗或易受其最坏结果的影响。胎儿脑和CNS的生物标志物 阿片类药物暴露期间的发育对于决定哪些婴儿需要阿片类药物治疗非常有价值 为NAS和阿片类药物暴露的婴儿进行个性化的风险评估。他们还可以揭示 导致妊娠期间阿片类药物暴露最严重影响的生物学途径。 来源于胎脑和中枢神经系统(FNEV)的细胞外囊泡(EV)可以穿过神经系统, 在一些实施方案中,所述载体可以是胎儿/胎盘屏障,并且可以从母体血液中分离。它们是一个强大的可访问工具, 提供胎儿神经发育和损伤的见解。然而,电动汽车是高度异质性的, 一组表面蛋白和囊内货物,如RNA。目前的分离和研究方法 EV缺乏必要的灵敏度和精确度来表征EV亚群。应对当前 EV分析的局限性,我们开发了一种高通量的单EV流分析仪和分选仪, 检测单个染料分子。 这种新的技术能力使我们能够精确地定义妊娠期间血浆FNEV的特征。 我们的研究可能会导致测定,定义NAS风险出生前,并带来新的见解的机制, 胎儿脑损伤的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel T Chiu其他文献

Daniel T Chiu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel T Chiu', 18)}}的其他基金

Predicting neonatal health outcomes from placental and fetal brain extracellular vesicles in pregnant opioid users
通过妊娠阿片类药物使用者的胎盘和胎儿脑细胞外囊泡预测新生儿健康结果
  • 批准号:
    10747661
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
An HIV Self-Test
艾滋病毒自检
  • 批准号:
    10064842
  • 财政年份:
    2020
  • 资助金额:
    $ 71.81万
  • 项目类别:
An HIV Self-Test
艾滋病毒自检
  • 批准号:
    10242940
  • 财政年份:
    2020
  • 资助金额:
    $ 71.81万
  • 项目类别:
An HIV Self-Test
艾滋病毒自检
  • 批准号:
    10461827
  • 财政年份:
    2020
  • 资助金额:
    $ 71.81万
  • 项目类别:
Single Extracellular Vesicle Sorting and Analysis
单个细胞外囊泡分选和分析
  • 批准号:
    10376602
  • 财政年份:
    2019
  • 资助金额:
    $ 71.81万
  • 项目类别:
Single Extracellular Vesicle Sorting and Analysis
单个细胞外囊泡分选和分析
  • 批准号:
    9811315
  • 财政年份:
    2019
  • 资助金额:
    $ 71.81万
  • 项目类别:
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia
开发生物信息学和微流体单细胞方法来研究急性髓系白血病的瘤内异质性
  • 批准号:
    10533290
  • 财政年份:
    2018
  • 资助金额:
    $ 71.81万
  • 项目类别:
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia
开发生物信息学和微流体单细胞方法来研究急性髓系白血病的瘤内异质性
  • 批准号:
    10601429
  • 财政年份:
    2018
  • 资助金额:
    $ 71.81万
  • 项目类别:
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia
开发生物信息学和微流体单细胞方法来研究急性髓系白血病的瘤内异质性
  • 批准号:
    10058820
  • 财政年份:
    2018
  • 资助金额:
    $ 71.81万
  • 项目类别:
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia
开发生物信息学和微流体单细胞方法来研究急性髓系白血病的瘤内异质性
  • 批准号:
    10308466
  • 财政年份:
    2018
  • 资助金额:
    $ 71.81万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 71.81万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了